RPL4P4 and central nervous system cancer: Assessment of the prognostic value of RPL4P4 expression in glioma patients subgrouped by WHO grade, 1p/19q codeletion, IDH mutation status, recurrence, and age showed that high expression of RPL4P4 was associated with poor prognosis in all of these groups (Figures 3(a)–3(h)).